Remicade® infliximab

Find a Specialist | Contact Us | For Healthcare Professionals

Psoriasis
Rheumatoid Arthritis
Psoriatic Arthritis
Crohn's Disease
Pediatric Crohn’s Disease
Ulcerative Colitis
Ankylosing Spondylitis
Important Safety Information

 

Pediatric Crohn’s Disease Clinical Study

REMICADE is for children (ages 6-17) with moderate to severe Crohn's disease who haven't responded well to other therapies. REMICADE has been approved for the treatment of pediatric Crohn’s disease, based on the REACH clinical study. To read more about this clinical study and its results, please visit the following resource.

REACH study overview




IMPORTANT SAFETY INFORMATION | Privacy Policy | Legal Notice | Site Map | About Centocor Ortho Biotech Inc.

© Centocor Ortho Biotech Inc. 1999-2010
This site is published by Centocor Ortho Biotech Inc. which is solely responsible for its contents.
It is intended for residents from the United States.
Last Updated: January 19, 2009